Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: A Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study

Leukemia and Lymphoma

Volumn 54, Issue 1, 2013, Pages 53-57

  Carella, Angelo M ^a   De Souza, Carmino A ^b,m   Luminari, Stefano ^c   Marcheselli, Luigi ^c   Chiappella, Annalisa ^d   Di Rocco, Alice ^e   Cesaretti, Marina ^c   Rossi, Andrea ^f   Rigacci, Luigi ^g   Gaidano, Gianluca ^h   Merli, Francesco ⁱ   Spina, Michele ^j   Stelitano, Caterina ^k   Hohaus, Stefan ^l   Barbui, Anna ^f   Puccini, Benedetta ^g   Miranda, Eliana C ^b   Guida, Annalisa ^c   Federico, Massimo ^c  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d MOLINETTE HOSPITAL   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f OSPEDALI RIUNITI   (Italy)

^g CAREGGI UNIVERSITY HOSPITAL   (Italy)

^h UNIVERSITY OF EASTERN PIEDMONT   (Italy)

ⁱ S MARIA NUOVA HOSPITAL   (Italy)

^j CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^k BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^l CATHOLIC UNIVERSITY   (Italy)

^m Grupo de Estudos em Moléstias Onco Hematológicas GEMOH   (Brazil)

more..

Author keywords

Diffuse large B cell lymphoma; Gender; IPI prognosis; Overall survival; Retrospective study

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BRAZIL; CANCER COMBINATION CHEMOTHERAPY; DRUG CLEARANCE; FEMALE; FOLLOW UP; GENDER; HUMAN; ITALY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; PROGNOSIS; RETROSPECTIVE STUDIES; SEX FACTORS; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 84870873659     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.691482     Document Type: Article

References (31)

1. Campo E, Harris NL, et al. WHO classifi cation of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008.
2. Coiffi er B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diff use large-B-cell lymphoma. N Engl J Med 2002 ; 346: 235- 242. (Pubitemid 34438862)
3. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diff use large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23: 5027 - 5033. (Pubitemid 46224009)
4. P freundschuh M, T rumper L, O sterborg A,et al. C HOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diff use large-B-cell lymphoma: A randomised controlled trial by the MabTh era International Trial (MInT) Group. Lancet Oncol 2006; 7: 379- 391.
5. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987- 994.
6. Ziepert M, Hasenclever D, Kuhnt E, et al. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20 - B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28: 2373 - 2380.
7. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diff use large B-cell lymphoma treated with R-CHOP. Blood 2007; 109: 1857 - 1861. (Pubitemid 46348180)
8. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diff use large B-cell lymphoma identifi ed by gene expression profi ling. Nature 2000; 403: 503 - 511. (Pubitemid 30082188)
9. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profi ling to predict survival after chemotherapy for diff use large-Bcell lymphoma. N Engl J Med 2002; 346: 1937- 1947. (Pubitemid 34651353)
10. Hans CP, Weisenburger DD, Greiner TC, et al. Confi rmation of the molecular classifi cation of diff use large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275 - 282. (Pubitemid 38029949)
11. Hasselblom S, Ridell B, Nilsson-Ehle H, et al. The impact of gender, age and patient selection on prognosis and outcome in diff use large B-cell lymphoma - a population-based study. Leuk Lymphoma 2007; 48: 736 - 745. (Pubitemid 46605546)
12. H asenclever D, D iehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin' s Disease. N Engl J Med 1998; 339: 1506- 1514.
13. Federico M, Vitolo U, Zinzani PL, et al. Prognosis of follicular lymphoma: A predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood 2000; 95: 783 - 789. (Pubitemid 30062696)
14. Catovsky D, Fooks J, Richards S. Prognostic factors in chronic lymphocytic leukaemia: The importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC Working Party on Leukaemia in Adults. Br J Haematol 1989; 72: 141 - 149. (Pubitemid 19151132)
15. O sby E, A skling J, L andgren O,et al. P arental longevity and prognosis in elderly patients with aggressive non-Hodgkin's lymphoma. Acta Oncol 2004; 43: 297 - 301. (Pubitemid 38757053)
16. Riihijarvi S, Taskinen M, Jerkeman M, et al. Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy. Eur J Haematol 2011; 86: 124- 128.
17. Ngo L, Hee SW, Lim LC, et al. Prognostic factors in patients with diff use large B cell lymphoma: Before and after the introduction of rituximab. Leuk Lymphoma 2008; 49: 462- 469. (Pubitemid 351298329)
18. Pfreundschuh M. How I treat elderly patients with diff use large B-cell lymphoma. Blood 2010; 116: 5103 - 5110.
19. Gisselbrecht C, Glass B, Laurent G, et al. Maintenance with rituximab after autologous stem cell transplantation in relapsed patients with CD20 diff use large B-cell lymphoma (DLBCL): CORAL fi nal analysis. J Clin Oncol 2011; 29(Suppl.): Abstract 8004.
20. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457 - 481.
21. C ox D. R egression models and life-tables. J R Stat Soc B 1972; 34: 187 - 220.
22. Altman DG, Andersen PK. Bootstrap investigation of the stability of a Cox regression model. Stat Med 1989; 8: 771 - 783. (Pubitemid 19178937)
23. Volinsky CT, Raftery AE. Bayesian information criterion for censored survival models. Biometrics 2000; 56: 256 - 262. (Pubitemid 30165117)
24. Gonen H. Concordance probability and discriminatory power in proportional hazards regression. Biometrika 2005; 92: 965 - 970.
25. S ehn LH, S cott DW, C hhanabhai M,et al. I mpact of concordant and discordant bone marrow involvement on outcome in diff use large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2011; 29: 1452 - 1457.
26. M icheli A, C iampichini R, O beraigner W,et al. The advantage of women in cancer survival: An analysis of EUROCARE-4 data. Eur J Cancer 2009; 45: 1017 - 1027.
27. Pfreundschuh MM, Zeyanalova S. Male sex is associated with lower rituximab trough serum levels and evolves as a signifi cant prognostic factor in elderly patients with DLBCL treated with RCHOP: Results from 4 prospective trials of the German High-Grade Non Hodgkin-Lymphoma Study Group (DSHNHL). Blood 2009 ; 114(Suppl. 1): Abstract 3715.
28. Ng CM, Bruno R, Combs D, et al. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 2005; 45: 792 - 801. (Pubitemid 40875331)
29. Ternant D, Aubourg A, Magdelaine-Beuzelin C, et al. Infl iximab pharmacokinetics in infl ammatory bowel disease patients. Th er Drug Monit 2008; 30: 523 - 529.
30. L u JF, B runo R, E ppler S,et al. C linical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 2008; 62: 779- 786.
31. C artron G, T rappe RU, S olal-Celigny P,et al. I nterindividual variability of response to rituximab: From biological origins to individualized therapies. Clin Cancer Res 2011; 17: 19- 30.